INTRODUCTION
Pseudophakic cystoid macular edema (PCME), or Irvine-Gass syndrome, is a common complication following cataract surgery (1) . It was first described in 1953 by Irvine, and in 1966, Gass and Norton published an angiographic study of its characteristics (1, 2) . The incidence of clinical (symptomatic) PCME has been greatly reduced because of its advances in surgical techniques (approximately 0.1%-2.35%), and most cases of PCME have spontaneous resolution (2) . Majority of patients remain asymptomatic without active inflammation on fundus examination and optical coherence tomography (OCT) (3) . However, subclinical PCME is detected in almost 30% of patients with postsurgical angiography and a further 11%-41% patients with OCT (4) . The pathogenesis of PCME remains obscure. Most investigators agree that inflammation is the main etiologic factor in the development of PCME (5) . Inflammatory mediators disrupt the blood-aqueous barrier (BAB) and blood-retinal barrier (BRB), leading to an amplification of retinal permeability and the development of PCME (2, 5) . No recent significant studies have been conducted to establish the best therapeutic options for treating this disorder (4) . Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids represent the most common first-line treatments (4, 6) . Antiangiogenic therapy, sub cutaneous injections of interferon α2a, hyperbaric therapy, and vitrectomy are also therapeutic options (4, 5) . The dexamethasone implant (DEX implant; Ozurdex; Allergan, USA) is a 0.7 mg biodegradable intravitreal implant that delivers dexamethasone into the vitreous and retina. The drug acts on all inflammatory mediators and has been approved by the US Food and Drug Administration (FDA) for the treat ment of macular edema (ME) secondary to retinal vein occlusion (RVO) and for non-infectious posterior uveitis (4) . The DEX implant has also been indicated for the treatment of diabetic ME in patients who are pseudophakic or are phakic and scheduled for cataract surgery (4) . In this study, we describe a case series of six patients who were previously diagnosed with PCME and treated with DEX implants.
CASE REPORT
This is a retrospective small case series of six patients who were diagnosed with PCME and treated with DEX implants at the Centro Brasileiro de Cirurgia de Olhos (Goiânia, Goiás, Brazil) and Centro Bra sileiro da Visão (Brasília, Distrito Federal, Brazil) 
ABSTRACT
Pseudophakic cystoid macular edema (PCME) is a common complication following cataract surgery. Although majority of patients with PCME remain asymptomatic, it remains an important cause of vision loss after cataract surgery. The pathogenesis of PCME remains unclear, but most authors agree that inflammation plays a major role in its development. There is no standard algorithm for treatment procedures for PCME. A biodegradable 0.7 mg dexamethasone intravitreal implant can be used to deliver medication into the posterior segment of eyes. This drug acts on all inflammatory mediators and has been approved for the treatment of macular abnormalities secondary to retinal vein occlusion and for non-infectious posterior uveitis. In this case series, we report six patients who presented with PCME and were treated with a 0.7 mg dexamethasone intravitreal implant. No patient presented significant changes in intraocular pressure during the follow-up period.
DISCUSSION
The pathogenesis of PCME remains unclear, but it is generally agreed that inflammation plays a major role in its development (2, 4, 5, 7) . Breakdown of the BAB and BRB may be associated with diabetes and glaucoma (2) . Patients with diabetes, particularly those with diabetic retinopathy, are at an increased risk of developing PCME (8) . In general, cataract surgery results in intraocular inflammation produced by inflammatory mediators that cause increased expression of vascular endothelial growth factor (VEGF), which potently induces increased permeability of the perifoveal capillary net and breakdown of the BRB (5) . However, to date, no studies have shown increased ocular VEGF levels in patients with PCME in the absence of ischemic ocular disease (2) . The DEX implant has been approved by the US FDA for the treatment of ME secondary to RVO, for non-infectious posterior uveitis and for the treatment of diabetic ME in patients who are pseudophakic or are phakic and scheduled for cataract surgery (4) . Dexamethasone has a six-fold more potent anti-inflammatory pro file than triamcinolone acetonide (8) . A phase II study on the dexamethasone drug delivery system conducted a subgroup analysis that included patients with PCME and patients with uveitis (4, 9) . A visual gain of at least 15 ETDRS letters was reported at the 90-day follow-up in 53.8% of the patients who were treated with 0.7 mg intravitreal dexamethasone implants (9) . In the EPISODIC study, cases of ocular hypertension were reported but were controlled with pressure-lowering me dications. No filtering surgery was required (4) . In our group of pa tients, including two with previously diagnosed glaucoma, there was no need to change their current therapies.
In conclusion, when considering the relationship between inflammation and the development of PCME, it is reasonable to hypothesize that DEX implants may offer a promising treatment option for patients who develop PCME following cataract surgery. Controlled studies with larger sample sizes should be performed to confirm these preliminary findings. 
